DiaMedica Therapeutics (NASDAQ:DMAC) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

DiaMedica Therapeutics (NASDAQ:DMAC) posted its quarterly earnings data on Monday. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01), Zacks reports.

DiaMedica Therapeutics Price Performance

Shares of NASDAQ DMAC opened at $5.99 on Tuesday. The stock has a fifty day moving average price of $5.96 and a 200 day moving average price of $5.09. DiaMedica Therapeutics has a 1-year low of $2.14 and a 1-year high of $6.82. The company has a market cap of $256.14 million, a PE ratio of -10.70 and a beta of 1.52.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.